Brief: NGM Bio Reports Topline Results From 24-Week Phase 2B Alpine 2/3 Study Of Aldafermin In Nash

NGM Biopharmaceuticals

24/05/2021 12:11

May 24 (Reuters) - NGM Biopharmaceuticals Inc  NGM.O :
    * NGM BIO REPORTS TOPLINE RESULTS FROM 24-WEEK PHASE 2B
ALPINE 2/3
STUDY OF ALDAFERMIN IN NASH
    * NGM BIOPHARMACEUTICALS INC - STUDY DID NOT MEET PRIMARY
ENDPOINT
OF FIBROSIS IMPROVEMENT BY >1 STAGE WITH NO WORSENING OF NASH
VERSUS PLACEBO
    * NGM BIOPHARMACEUTICALS INC - STATISTICAL SIGNIFICANCE
ACHIEVED
VERSUS PLACEBO ON CERTAIN SECONDARY ENDPOINTS
    * NGM BIOPHARMACEUTICALS INC - PLANS NOT TO PURSUE PHASE 3
CLINICAL DEVELOPMENT OF ALDAFERMIN IN F2/F3 NASH
    * NGM BIOPHARMACEUTICALS INC - WILL FOCUS ON ITS GROWING
OPHTHALMOLOGY AND ONCOLOGY PORTFOLIO
    * NGM BIOPHARMACEUTICALS INC - ALDAFERMIN WAS GENERALLY WELL
TOLERATED WITH AN OVERALL SAFETY PROFILE SIMILAR TO PLACEBO

Source text for Eikon:  ID:nGNX3HDH5R 
Further company coverage:  NGM.O 

 ((Reuters.Briefs@thomsonreuters.com;))